Pre-made Simtuzumab benchmark antibody ( Whole mAb, anti-LOXL2 therapeutic antibody, Anti-LOR/LOR2/WS9-14 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Simtuzumab biosimilar, Whole mAb, Anti-LOXL2 Antibody: Anti-LOR/LOR2/WS9-14 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.
| Products Name (INN Index) | Pre-Made Simtuzumab biosimilar, Whole mAb, Anti-LOXL2 Antibody: Anti-LOR/LOR2/WS9-14 therapeutic antibody |
|---|---|
| INN Name | Simtuzumab |
| Target | LOXL2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Arresto Biosciences,Gilead Sciences |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Colorectal cancer,Hepatic fibrosis,Idiopathic pulmonary fibrosis,Liver cirrhosis,Myelofibrosis,Non-alcoholic steatohepatitis,Pancreatic cancer,Primary sclerosing cholangitis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | LOXL2 |
| Package |
